RT Journal Article
SR Electronic
T1 Reemergence of Oropouche virus between 2023 and 2024 in Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.27.24310296
DO 10.1101/2024.07.27.24310296
A1 Scachetti, Gabriel C
A1 Forato, Julia
A1 Claro, Ingra M.
A1 Hua, Xinyi
A1 Salgado, Barbara B.
A1 Vieira, Aline
A1 Simeoni, Camila L.
A1 Barbosa, Aguyda R. C.
A1 Rosa, Italo L.
A1 de Souza, Gabriela F.
A1 Fernandes, Luana C.N.
A1 de Sena, Ana Carla H.
A1 Oliveira, Stephanne C.
A1 Singh, Carolina M.L
A1 de Lima, Shirlene T.
A1 de Jesus, Ronaldo
A1 Costa, Mariana A.
A1 Kato, Rodrigo B.
A1 Rocha, Josilene F.
A1 Santos, Leandro C.
A1 Rodrigues, Janete T.
A1 Cunha, Marielton P.
A1 Sabino, Ester C.
A1 Faria, Nuno R.
A1 Weaver, Scott C.
A1 Romano, Camila M.
A1 Lalwani, Pritesh
A1 Proenca-Modena, Jose Luiz
A1 de Souza, William M
YR 2024
UL http://medrxiv.org/content/early/2024/07/30/2024.07.27.24310296.abstract
AB Background: Oropouche virus (OROV; species Orthobunyavirus oropoucheense) is an arthropod-borne virus that has caused outbreaks of Oropouche fever in Central and South America since the 1950s. This study investigates virological factors contributing to the reemergence of Oropouche fever in Brazil between 2023 and 2024. Methods: In this study, we combined OROV genomic, molecular, and serological data from Brazil from 1 January 2015 to 29 June 2024, along with in vitro and in vivo characterization. Molecular screening data included 234 patients with febrile illness or central nervous system (CNS) manifestations between December 2023 and May 2024 from the Amazonas State. Genomic data comprised two genomic OROV sequences from patients. Serological data were obtained from neutralizing antibody tests comparing the prototype OROV strain BeAn 19991 and the 2024 epidemic strain. Epidemiological data included aggregated cases reported to the Brazilian Ministry of Health from 1 January 2014 to 29 June 2024. Findings: In 2024, autochthonous OROV infections were detected in previously non-endemic areas across all five Brazilian regions. Cases were reported in 19 of 27 federal units, with 83.2% (6,895 of 8,284) of infections in Northern Brazil and a nearly 200-fold increase in incidence compared to reported cases over the last decade. We detected OROV RNA in 10.8% (10 of 93) of patients with febrile illness and 2.1% (3 of 141) of patients with CNS manifestations between December 2023 and May 2024 in Amazonas. We demonstrate that the 2023-2024 epidemic was caused by a novel OROV reassortant that replicated approximately 100-fold higher titers in mammalian cells compared to the prototype strain. The 2023-2024 OROV reassortant displayed plaques earlier than the prototype, produced 1.7 times more plaques, and plaque sizes were 2.5 larger compared to the prototype. Furthermore, serum collected in 2016 from previously OROV-infected individuals showed at least a 32-fold reduction in neutralizing capacity against the reassortment strain compared to the prototype. Interpretation: These findings provide a comprehensive assessment of Oropouche fever in Brazil and contribute to a better understanding of the 2023-2024 OROV reemergence. The recent increased incidence may be related to a higher replication efficiency of a new reassortant virus that also evades previous immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJLPM is supported by Sao Paulo Research Foundation (#2022/10442-0), and National Council for Scientific and Technological Development (CNPq, #309971/2023-3). WMdS is supported by Burroughs Wellcome Fund - Climate Change and Human Health Seed Grants (#1022448), and Wellcome Trust - Digital Technology Development Award in Climate Sensitive Infectious Disease Modelling (#226075/Z/22/Z). NRF was supported by a Wellcome Trust and Royal Society Sir Henry Dale Fellowship (grant no. 204311/Z/16/Z). NRF and ECS are supported by a Medical Research Council-Sao Paulo Research Foundation - CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0). SCW was supported by NIH grant R24 AI120942. CMR is supported by Sao Paulo Research Foundation (#2022/10408-6). IMC was supported by Sao Paulo Research Foundation (#2023/11521-3). CLS was supported by Sao Paulo Research Foundation (#2022/00723-1). MSB is supported by Fundacao de Amparo a Pesquisa do Estado do Amazonas (# 083/2021). LLAS received support from Fundacao de Amparo a Pesquisa do Estado do Amazonas. PL is supported by Fundacao de Amparo a Pesquisa do Estado do Amazonas (POSGRAD, CT and I AREAS PRIORITARIAS, INICIATIVA AMAZONIA +10, CHAMADA ERC 2022 and PEX-CT and I/FAPEAM); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Funding 001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures followed the ethical standards of the responsible committee on human experimentation and were approved by the ethics committees from the Federal University of Amazonas, Brazil (approval numbers 5.876.612 and 6.629.451) and Nilton Lins University (2.636.421). All necessary patient/participant consent (including consent to publish) has been obtained and the appropriate institutional forms have been archived and any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group and cannot be used to identify individualsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll statistical computing analyses were conducted using the R project. R packages necessary for analysis and visualization include: readxl, tidyverse, dylyr, zoo, scales, lubridate, tmap, sf, ggplot2, ggbreak, ggpubr, stringr. No custom code was developed. New sequences have been deposited in GenBank with accession numbers PP992525 - PP992530.